C6O — Clovis Oncology Share Price
Last trade - 00:00- €2.17m
- €538.48m
- $148.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -157.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 55.51 | 95.39 | 143.01 | 164.52 | 148.76 | 130.42 | 137.38 | 352.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286 is a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
Directors
- Ginger Graham NEC (66)
- Patrick Mahaffy PRE (58)
- Gillian Ivers - Read CFD (67)
- Daniel Muehl CFO (58)
- Thomas Harding EVP (47)
- Paul Gross EVP (56)
- Ann Bozeman EVP
- Lindsey Rolfe EVP (53)
- Brian Atwood IND (68)
- Robert Azelby IND (53)
- James Blair IND (81)
- Richard Fair IND (52)
- Keith Flaherty IND (50)
- Paul Klingenstein IND (65)
- Edward Mckinley IND (69)
- Ronit Simantov IND (56)
- Thorlef Spickschen IND (80)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- April 20th, 2009
- Public Since
- November 16th, 2011
- No. of Shareholders
- 26
- No. of Employees
- 413
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Frankfurt Stock Exchange
- Shares in Issue
- 144,955,263
- Address
- Suite 100, 2525 28Th Street, BOULDER, 80301
- Web
- https://clovisoncology.com/
- Phone
- +1 3036255000
- Auditors
- Ernst & Young LLP
Upcoming Events for C6O
Similar to C6O
4Sc AG
Frankfurt Stock Exchange
CureVac NV
Frankfurt Stock Exchange
Deutsche Biotech Innovativ AG
Frankfurt Stock Exchange
Diagonal Bio AB
Frankfurt Stock Exchange
Elanix Biotechnologies AG
Frankfurt Stock Exchange
FAQ
As of Today at 01:06 UTC, shares in Clovis Oncology are trading at €0.02. This share price information is delayed by 15 minutes.
Shares in Clovis Oncology last closed at €0.02 and the price had moved by -98.87% over the past 365 days. In terms of relative price strength the Clovis Oncology share price has underperformed the FTSE Global All Cap Index by -98.97% over the past year.
The overall consensus recommendation for Clovis Oncology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Clovis Oncology does not currently pay a dividend.
Clovis Oncology does not currently pay a dividend.
Clovis Oncology does not currently pay a dividend.
To buy shares in Clovis Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.02, shares in Clovis Oncology had a market capitalisation of €2.17m.
Here are the trading details for Clovis Oncology:
- Country of listing: Germany
- Exchange: FRA
- Ticker Symbol: C6O
Based on an overall assessment of its quality, value and momentum Clovis Oncology is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Clovis Oncology is €1.78. That is 11777.19% above the last closing price of €0.02.
Analysts covering Clovis Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$1.68 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clovis Oncology. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -74.69%.
As of the last closing price of €0.02, shares in Clovis Oncology were trading -92.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Clovis Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Clovis Oncology's management team is headed by:
- Ginger Graham - NEC
- Patrick Mahaffy - PRE
- Gillian Ivers - Read - CFD
- Daniel Muehl - CFO
- Thomas Harding - EVP
- Paul Gross - EVP
- Ann Bozeman - EVP
- Lindsey Rolfe - EVP
- Brian Atwood - IND
- Robert Azelby - IND
- James Blair - IND
- Richard Fair - IND
- Keith Flaherty - IND
- Paul Klingenstein - IND
- Edward Mckinley - IND
- Ronit Simantov - IND
- Thorlef Spickschen - IND